Embryonic stem (ES) cells can be induced to differentiate into motor neurons (MN). Animal models resembling MN degeneration and paralysis observed in familial amyotrophic lateral sclerosis (ALS) have been previously reported. In this work, we aimed to investigate whether transplanted MN could prevent motor deterioration in transgenic rats expressing a mutant form of human superoxide dismutase 1 (hSOD1 G93A ) associated with inherited ALS. Mouse ES cells were differentiated to neurons that express green fluorescent protein (GFP) under the promoter of the MN-specific gene hb9, as well as molecular markers indicative of MN identity. Cells were grafted into the lumbar spinal cord of adult wild-type (WT) or hSOD1 G93A rats at 10 weeks of age, when transgenic animals are presymptomatic. Grafted cells with MN phenotype can survive for at least 1 week in hSOD1 G93A animals. To quantitatively evaluate motor performance of WT and transgenic rats, we carried out weekly rotarod tests starting when the animals were 14 weeks old. Sham and grafted WT animals showed no decline in their ability to sustain themselves on the rotating rod. In contrast, sham hSOD1 G93A rats decreased in motor performance from week 16 onwards, reaching paralysis by week 19 of age. In grafted transgenic animals, there was a significant improvement in rotarod competence at weeks 16 and 17 when compared to sham hSOD1 G93A . However, in the following weeks, transplanted hSOD1 G93A rats showed motor deterioration and eventually exhibited paralysis by week 19. At end-stage, we found only a few endogenous MN in sham and grafted hSOD1 G93A rats by cresyl violet staining; no choline acetyl transferase-positive nor GFP-positive MN were present in grafted transgenic subjects. In contrast, WT rats analyzed at the same age possessed grafted GFP-positive MN in their spinal cords. These results strongly suggest that the transgenic hSOD1 G93A environment is detrimental to grafted MN in the long term.
INTRODUCTION
mutations in SOD1 are associated with FALS onset (1) . One of these mutations, human (h) SOD1 G93A has been expressed in transgenic animals (17,20) with pathologiAmyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that is characterized by the selective cal findings that have been extensively characterized and closely resemble the MN degeneration and paralysis obdeath of motor neurons (MN) in the brain and the spinal cord, leading to generalized weakness, muscle atrophy, served in ALS patients. Thus, these animals are useful models to study potential therapies. and paralysis (6) . Currently, there is no effective treatment for this illness, although riluzole can cause a marBecause of the selective loss of MN, cell replacement therapy is a possible treatment for ALS. Stem cells are ginal benefit by slowing disease progression (18, 27) . Approximately 90% of ALS cases are sporadic; in 10% self-renewing and can differentiate to specialized phenotypes. Embryonic stem (ES) cells are derived from the of patients a genetic linkage has been described, and therefore they are classified as familial ALS (FALS). In inner cell mass of embryos at the blastocyst stage, and are considered to be pluripotent because they can differfact, 20% of FALS cases are caused by dominant mutations in Cu/Zn superoxide dismutase 1 (SOD1) (33), an entiate into cells from the three germinal layers (15, 25) . It is well established that ES cells have the capacity to enzyme that converts the highly oxidizing superoxide to hydrogen peroxide and water. To date, more than 100 generate neuronal cells, and that upon transplantation 1172 LÓ PEZ-GONZÁ LEZ, KUNCKLES, AND VELASCO these neurons cause improvement of neurological defi-0.2% papain/1 mM L-cysteine solution, and the resulting cell suspension was either reseeded on Matrigel-coated cits in experimental animals (3, 7, 11, 12, 23, 32, 34, 37) . Induction of ES cells into neuronal subtypes in vitro replates with DFNK differentiation medium consisting of DMEM:F12 and neurobasal medium (Gibco) supplequires exposure of these cells to morphogens and growth factors that recapitulate in vivo differentiation. In the mented with 2-mercaptoethanol, penicillin-streptomycin solution (Gibco), and knockout serum replacement case of MN differentiation, ES cells are stimulated with retinoic acid (RA) and sonic hedgehog (SHH) (41). ES (Gibco) to perform immunocytochemistry analyses, or used for transplantation studies. cell-derived MN have all the molecular and functional characteristics of MN present in vivo (26) , and when
Immunocytochemistry and Proportion of MN transplanted, can integrate (19) and cause a functional in Differentiated Cultures recovery in animal models of paralysis different from ALS (11) .
To identify key markers of MN differentiation, immunocytochemistry analyses were performed on differIn FALS models, some studies report a recovery in treated animals and a delay in the progression of the entiated cultures as described previously (12, 28, 38) . Cells were washed three times with phosphate-buffered saline disease when human neural stem cells (hNSC) (42) , human umbilical cord cells (16), or bone marrow stem (PBS) and fixed with 4% paraformaldehyde for 20 min at room temperature. Cultures were washed three times cells (10) were used. In spite of the recovery observed with cell replacement strategies, it has become evident with PBS and blocked by incubation with 10% normal goat serum/0.3% Triton X-100 in PBS for 45 min. The that MN degeneration in animal models of ALS is not a cell autonomous process (8) . Several works have profollowing primary antibodies were used at the indicated dilutions in 10% serum/PBS: rabbit anti-GFP 1:500 vided evidence that the environment created by nonneuronal cells could be detrimental to MN in animal models (Molecular Probes, USA), mouse anti-β-tubulin III antibody 1:1000 (Covance, USA), mouse anti-islet1 (Isl1) of FALS (5, 13, 29) . ES cells comprise a hypothetically unlimited source in cell replacement therapies to generantibody 1:2 (Developmental Studies Hybridoma Bank, USA), and goat anti-choline acetyl transferase (ChAT) ate specific cell types lost due to disease or injury. In addition, MN differentiation from ES cells is efficiently antibody 1:200 (Chemicon, USA). Corresponding secondary antibodies coupled to Alexa 488 or Alexa 568 achieved by a well-established protocol. Therefore, the aim of this work was to differentiate mouse ES cells to (1:500; Molecular Probes, USA) were used. For ChAT detection, biotinylated anti-goat secondary antibody (1: MN that express green fluorescent protein (GFP), and to transplant them into the spinal cord of adult transgenic 100), followed by incubation with Texas red-avidin (1: 200; Vector Laboratories, USA) was required. To label rats that express hSOD1 G93A to evaluate their capacity to provide functional recovery. nuclei, 5 µM Hoechst 32258 dye was used. All experiments included cultures where primary antibodies were MATERIALS AND METHODS not added; unspecific staining was not observed in such Motor Neuron Differentiation Protocol negative controls. To estimate the proportion of MN induced by treatment of EBs with RA, alone or in combi-HBG3 mouse ES cells express GFP under the control of the hb9 promoter and are useful to identify neurons nation with SHH, we quantified the percentage of GPFpositive cells from the total cell population in different with a MN phenotype. HBG3 cells were differentiated as previously described (41). Briefly, HBG3 cells were experimental conditions: 1) 0.1% dimethyl sulfoxide (DMSO, RA vehicle); 2) 2 µM RA; 3) 2 µM RA + 20 expanded on mitotically inactive mouse embryonic fibroblasts cultured with knockout DMEM supplemented ng/ml SHH; 4) 2 µM RA + 50 ng/ml SHH; 5) 2 µM RA + 100 ng/ml SHH. with nonessential amino acids, 2-mercaptoethanol, penicillin-streptomycin solution (Gibco, USA), 15% ES cellGenotyping of hSOD1 G93A Transgenic Rats tested fetal calf serum (Wisent, Canada), and 1000 U/ml of leukemia inhibitory factor (LIF; Chemicon, USA) to All animal procedures were approved by the local animal use and care committee and complied with Meximaintain their pluripotency. They were subsequently plated on gelatin-coated tissue culture plates and grown can and NIH guidelines. Transgenic hSOD1 G93A animals were purchased from Taconic (USA). Nontransgenic litto 80% confluency whereupon they were tripsinized and seeded in suspension in bacterial plates to form emtermates were used as controls. Male transgenic rats were mated with wild-type (WT) Sprague-Dawley febryoid bodies (EBs). Such EBs were cultured in ES cell medium for 2 days and subsequently treated with 2 µM male rats, and the resulting offspring were genotyped by the presence of hSOD1 G93A through a genomic DNA RA (Sigma, USA), together with varying concentrations of recombinant human SHH (R&D Systems, USA), for PCR protocol recommended by the distributor. Rats were identified by subcutaneous implantation of a mi-4 additional days. Finally, EBs were dissociated using a crochip (Allflex). Tail biopsies from 1-month-old rats Tissue Preparation and Immunohistochemistry were digested in proteinase K and then diluted 1:20 in In order to analyze the spinal cord of WT and transsterile H 2 O, followed by heating at 95°C for 15 min.
genic animals (sham and transplanted groups), they were Two microliters were subjected to PCR amplification euthanized by a lethal injection of pentobarbital (70 mg/ using primers specific for hSOD1 (forward: 5′-CGCGA kg of body weight) at 19 weeks of age. Animals were CACAATCAAAGTGA-3′, reverse: 5′-CATGAGCCC first perfused with physiological saline to eliminate TAATCCATCCATC-3′) to determine the genotype of blood, and then with 4% paraformaldehyde in PBS for the animals. In transgenic animals, we observed deteriofixation. The spinal cord was dissected to preserve only ration of motor abilities beginning with difficulty in posthe lumbar portion. Tissue was postfixed with paraforterior limb movement by 16 weeks of age and ultimately maldehyde and cryoprotected in 30% sucrose. Coronal paralysis by week 19.
sections of 30 µm were made close to the injection site. We analyzed the spinal cord of transplanted animals by Transplantation of MN Derived From ES Cells staining with 0.1% cresyl violet solution as described Transgenic and WT rats were transplanted at 10 previously (9) and by immunohistochemistry for ChAT weeks of age when hSOD G93A animals were presympand GFP to localize transplanted cells, either 1 week tomatic. One day prior to the surgical procedure, after grafting or at terminal stage when animals were cyclosporin A (10 mg/kg of body weight daily) was inparalyzed. jected IP, and this treatment continued daily until rats were euthanized. For transplantation, animals were
Statistical Analysis deeply anesthetized with sevofluorane (5% for inducAll in vitro data are presented as mean ± SEM from tion, 1% for maintenance) with the aid of a vaporizer.
at least three independent experiments. The number of An incision was made above the lumbar region to exanimals used per transplantation group was 4 to 8. We pose the vertebrae. The vertebral column was secured to performed ANOVA followed by Fisher post hoc test, a stereotactic frame with the aid of clamps (Stoelting, and considered significant differences when p < 0.05. USA) to perform laminectomy of L5. A small cut of the meninges was made to allow transplantation. Cell RESULTS suspensions of differentiated ES cells were loaded on a MN Differentiation microsyringe to unilaterally transplant 1 × 10 5 cells in 1 µl into the ventral gray matter (0.5 mm lateral to the HBG3 ES cells were derived from transgenic mice that express GFP under the control of the MN-specific midline and 1.5 mm ventral from the dorsal surface of the spinal cord). Sham rats were injected with 1 µl of hb9 promoter. Previous reports demonstrated that treatment of EBs with RA and SHH induced MN differentia-DFNK medium. We performed the transplantation procedure in a cohort (n = 4) of transgenic hSOD1 G93A rats tion of these ES cells (26, 41) . Treatment with 2 µM RA and 100 ng/ml SHH resulted in the appearance of GFP + that received cells previously labeled with 5 µM Hoechst 32258; these animals were sacrificed 1 week cells in the EBs (Fig. 1A , B), which upon dissociation and replating preserved GFP expression and neuronal later to verify transplant location and to establish the presence of ChAT + and GFP + cells. In addition, the folmorphology (Fig. 1C) . In dissociated EBs, we quantified the percentage of GFP + cells after incubation with lowing groups were euthanized at 9 weeks postsurgery: WT sham (n = 4), WT grafted (n = 4), hSOD1 G93A sham DMSO (the vehicle for RA), 2 µM RA, or with RA plus increasing concentrations of SHH. In DMSO-treated (n = 4), and hSOD1 G93A grafted (n = 8). We performed histological analysis of these groups when transgenic cultures GFP + cells represented less than 1% of total cells. This proportion increased with addition of RA hSOD1 G93A were at the terminal stage of the disease. only. In addition, we observed a significant dose-depenMotor Function Test dent increase in the proportion of GFP + MN, reaching a peak at 16% of the total population with 2 µM RA and In order to assess motor function the rotarod test was performed as described (9) . This test consists of placing 100 ng/ml SHH (Fig. 1D) . To further confirm the MN phenotype of GFP cells, we determined the presence of the rats on a rotating rod with an initial velocity of 10 rpm with an acceleration speed of 0.2 rpm/s until they molecular markers characteristic of this neuronal type through immunocytochemical analyses. In cells dissocifall off. Each week we recorded the time (in seconds) that the animals were able to sustain themselves on the ated from RA/SHH-treated EBs and plated on Matrigelcoated surface, we found that GFP + cells coexpressed rod, beginning at 14 weeks of age in sham and transplanted groups. This trial allowed us to establish the onthe neuronal marker β-tubulin III ( Fig. 2A) , and the MN transcription factor Isl1 ( Mouse ES cells differentiate to motor neurons with the addition of RA and SHH. Mouse HBG3 ES cells, wherein the hb9 promoter controls green fluorescent protein (GFP) expression, were used to form embryoid bodies (EBs), which upon treatment with 2 µM retinoic acid (RA)/100 ng/ml sonic hedgehog (SHH) contained GFP + cells (A); phase contrast of the same field is shown in (B). This GFP expression (green) was preserved in cells with neuronal morphology after dissociation of EBs and replating. Nuclei were labeled with Hoechst 32258 and are shown in blue (C); images are representative of five independent experiments. Different conditions were assayed to establish the proportion of GFP + cells after treatment with: 1) dimethyl sulfoxide (DMSO), vehicle for RA; 2) 2 µM RA; 3) 2 µM RA in combination with 20, 50, or 100 ng/ml of SHH. Significant increases in the proportion of GFP + cells were found when EBs were treated with 2 µM RA/50 ng/ml SHH and with 2 µM RA/100 ng/ml SHH (D). Mean ± SEM from three independent experiments. *p < 0.05 relative to DMSO. Scale bar: 50 µm (applies to A-C).
MN Transplantation
close to the ontogenic site of MN (Fig. 3A, B) . Transplanted cells were visualized by nuclear Hoechst stainCells obtained from EBs after 2 µM RA/100 ng/ml ing. Some of these cells were GFP and ChAT double SHH treatment were used to transplant transgenic positive, indicating their foreign origin and MN identity hSOD1 G93A rats at 10 weeks of age, when no motor alterrespectively ( Fig. 3C-F) . Close to the graft, we also ations were apparent. Animals received 1 × 10 5 differenfound ChAT + Hoechst − GFP − endogenous MN (Fig. 3F ). tiated cells in the ventral horn of the lumbar spinal cord (below L5 vertebra). In parallel, transgenic animals were
Rotarod Test injected with cell culture medium (sham group) in the same spinal region. In order to verify the injection site,
We then examined the therapeutic capacity of ES cell-derived MN to prevent motor alterations in transcell suspensions labeled with Hoechst 32258 were introduced into transgenic hSOD1 G93A recipients. Seven days genic rats that resemble FALS. The rotarod test was employed to evaluate the motor performance of sham or later, four animals were sacrificed and the lumbar spinal cord recovered to obtain coronal sections. Labeled cells transplanted WT animals. We found that both groups remained on the rotating rod for over 100 s at all anawere located in the ventral portion of the spinal cord, lyzed ages regardless of having received ES cell-derived alyzed, following a trend similar to sham group. At this stage animals were euthanized to perform histological MN transplants or not (Fig. 4) . In sharp contrast, shamoperated hSOD1
G93A rats showed a clear decline in their analysis. capacity to remain running after 16 weeks of age and Histological Analysis of Spinal Cords they were finally paralyzed by week 19. Paralysis generally commences in a hindlimb after 16 weeks of age,
We analyzed the spinal cords of sham WT (n = 4) (Fig. 5A) and transgenic animals either with sham surgery and this causes a decreased performance in the rotarod test. Interestingly, the transgenic transplanted group (n = 4) (Fig. 5B) or grafted with MN (n = 8) (Fig. 5C ) by cresyl violet staining at week 19 of age. MN were showed a significant recovery of motor function (Fig. 4) on weeks 16 and 17 maintaining on the rotarod 130 ± 8 apparent by size and anatomical location in the ventral horn in sham WT rats, whereas the number of surviving and 130 ± 3 s, respectively, whereas sham animals remained for 91 ± 12 s (week 16) and 65 ± 15.5 s (week MN in hSOD1 G93A transgenic animals fell dramatically (remaining cells pointed with arrows in Fig. 5B and C) . 17; p < 0.05 between sham and grafted groups for both time points). However this recovery was transient as
In grafted groups, we sought surviving MN in hSOD1 G93A paralyzed animals and did not find GFP + nor ChAT + MN transplanted animals eventually showed a decreased performance on the rotarod test, and finally became parcells in the transplantation site (Fig. 5D ). To rule out . Transient motor recovery assessed by rotarod test after MN transplantation in transgenic hSOD1 G93A rats. Surgeries were performed when rats were 10 weeks old for all groups. Starting at week 14, animals were placed on a rotating rod with constant acceleration to measure the time animals were able to sustain themselves by walking/running. Wild-type (WT) groups showed no decline in motor performance up to 19 weeks of age. Sham hSOD1 G93A animals showed a decreased time on the rod commencing at week 16 and were completely paralyzed by week 19. Transplanted hSOD1 G93A animals were indistinguishable from WT at weeks 16 and 17, and remained on the rod significantly longer than sham hSOD1 G93A rats, but rapidly declined and were paralyzed at week 19 of age. Mean ± SEM from four animals for WT sham, WT grafted, and hSOD1 G93A sham and eight rats for hSOD1 G93A grafted. *p < 0.05 relative to sham hSOD1 G93A animals.
transplant degeneration or rejection in the spinal cord, tion in vivo: RA and SHH. We observed that after stimulation of EBs with 2 µM RA and 100 ng/ml SHH, difwe analyzed the presence of MN in WT animals. In contrast with findings in transgenic rats, we found ChAT/ ferentiated cells expressed markers indicative of MN commitment, such as β-tubulin III, Isl1, and ChAT. Fur-GFP double positive MN in WT animals grafted at 10 weeks of age and sacrificed when they were 19 weeks thermore, HBG3 cells used in this work express GFP under the transcriptional control of the hb9 promoter, old (Fig. 5E, F) , demonstrating that these cells can survive for more than 2 months in a nontransgenic environwhich upon differentiation allow identification of MN by GFP expression. We found that close to 20% of cells ment.
were GFP + , a proportion similar to that previously re-DISCUSSION ported (11, 41 G93A (B) and transplanted hSOD1 G93A (C) animals showed a marked decrease in the number of MN with only a few of these cells surviving (arrows in B and C). Ventral side is at the top in these micrographs. In paralyzed hSOD1
G93A grafted rats, we did not find GFP + nor ChAT + cells by confocal microscopy, indicating the loss of both transplanted and endogenous MN in the lumbar spinal cord (D); inset shows a phase contrast picture of this tissue, where the ventral portion is to the right. When we analyzed transplanted WT rats 9 weeks after grafting, we observed GFP + (E) and ChAT + (F) cells. In these animals, we found endogenous MN that were ChAT + /GFP − (indicated by arrows in E and F). Ventral is to the left in these last two images. Scale bar: 100 µm and 300 µm for inset in (D).
ChAT, confirming their MN identity. This suggests that life span. On the other hand, similar to our findings, the effects published in these studies were effective only for transplanted MN could stop motor deterioration in transplanted transgenic animals by functionally restoring lost a short period of time.
The transplantation procedure used here requires cut-MN. Interestingly, our results indicate that in hSOD1 G93A rats, transplanted cells caused a significant recovery as ting meninges to inject the cell suspension, allowing the entrance of immune cells to the central nervous system. evaluated with the rotarod test during weeks 16 and 17 of age (6-7 weeks after transplantation), when comXenografts are rejected by the host immune system through cellular responses (4). To prevent degeneration pared to sham animals. This improvement was transient, as at later stages all transgenic animals showed a deof transplanted cells, several immunosuppressive or immunomodulator molecules have been employed (4, 42) . crease in rotarod performance, and finally succumbed to paralysis. Several groups have transplanted stem cells in Calcineurin inhibitors such as cyclosporine A prevent the action of effector T cells. Transplantation of stem order to improve the motor deficits of transgenic rodents that express hSOD1 mice caused a functional recovery. They found that transgraft survival when cyclosporine was used as monotherapy even transiently (40) . The situation is different for planted cells can differentiate to neurons and integrate with other endogenous neurons. Bone marrow transplanintraspinal transplantation of transgenic rodents with human cells, where reports have shown variable (24, 36) or tation also induces a recovery in hSOD1 G93A mice (10). These results demonstrate that transplantation of stem no graft survival (42) in animals receiving only cyclosporine; combined immunosuppression or anti-CD4 antibodcells into FALS models causes recovery and increase ies promote human xenograft survival in hSOD1 G93A mice also in vitro evidence suggesting that mutated hSOD1 G93A microglia produce an increase of superoxide and peroxi- (42) . Other reports, however, show consistent mouse ES cell-derived xenograft implantation in the viral-damaged nitrite compared to the microglia of WT animals (5) . In vivo studies also show that transplanted WT microglia spinal cord (11, 19) , or the lesioned striatum of recipient WT rats immunosuppressed only with cyclosporine A can delay disease progression in transgenic hSOD1 G93A rodents (5) . Furthermore, in elegant chimeric studies, it (12,23,32). These findings, together with our results of consistent presence of grafts in WT rats 9 weeks postwas found that WT MN succumbed to cell death when surrounded by nonneuronal cells expressing mutant transplantation, show that cyclosporine is useful in protecting grafted cells in the spinal cord of nontransgenic hSOD1 G93A (8) . In addition, a selective toxicity of MN has been demonstrated by in vitro studies where human animals, and suggest that mutant hSOD1 G93A rats are different to WT animals in host-graft interactions unre-ES cell-derived MN were incubated with glial cells isolated from animals that express hSOD1 G93A (13). All lated to immunological rejection.
Transplanted MN did not extend axons out of the spithese data show that the hSOD1 G93A environment in the spinal cord is detrimental for endogenous and transnal cord, and therefore did not reach muscles. We suggest that the observed preservation in motor function planted MN. This notion is further supported by the fact that we found GFP-expressing cells 2 months postgraftcould be due to trophic support provided by the transplanted cells to the deteriorating endogenous MN. In ing in WT animals, indicating that transplanted MN can survive in nontransgenic animals. Other groups have reline with this argument, it has been reported that human neural precursor cells engineered to secrete glial-derived ported similar findings with survival times above 6 months (11, 19) . neurotrophic factor (hNPC GDNF ) and transplanted into the spinal cord of transgenic hSOD1 G93A rats, caused increased To achieve long-term recovery in transgenic hSOD1 G93A rats, it is important to accomplish some basic conditions. cholinergic markers of MN (24) . In addition, this same group observed that transplanted hNPC GDNF cells preFirst, cells must survive in the spinal cord of transgenic animals. One strategy to improve survival of these cells vented degeneration of endogenous MN in the spinal cord, even at the final stage of disease. However, animight be the cotransplantation of MN with mesenchymal stem cells. It is reported that these cells decreased mals in this study showed also eventual paralysis possibly because the transplanted cells could not prevent deastrogliosis and microglia activation that could be detrimental toward MN (39). Another possibility in the same generation of the neuromuscular junction (36) . Also, it has been reported that hNPC GDNF cells were able to pardirection is to optimize the in vivo survival of transplanted cells. For example, ES cells that express the tially protect dopaminergic neurons when transplanted 1 week after a unilateral lesion was induced with the dopaantiapoptotic protein Bcl-XL were differentiated to dopaminergic neurons and these proved to be more resismine toxin MPTP in monkeys (14). Mouse NPC transfected with Neurotrophin 3 produced recovery in mice tant to toxic insults than dopaminergic neurons derived from WT ES cells (35) . Also, viral delivery of vascular with dorsal spinal cord damage after transplantation (43) . Bone marrow stromal cells, which include mesenendothelial growth factor or insulin-like growth factor 1 in mutant hSOD1 transgenic animals delays paralysis chymal stem cells, have also been successfully used for the treatment of acute spinal cord injury with recovery onset and extends survival time (2, 21) . Secondly, another critical condition for achieving recovery is to creprobably mediated through the secretion of neurotrophins, axonal regeneration, or remyelination (30 graft, dibutyril cyclic AMP/rolipram (to inhibit myelinmediated repulsion of axon outgrowth) treatment, and GFP in grafted animals, suggesting that transplanted MN were also affected by the same hostile environment transplantation of NPC GDNF into the sciatic nerve to promote axonal growth towards muscle, they observed that that cause degeneration of endogenous MN. In a previous report, it was shown that degenerating MN, stained MN axons were extended outside the spinal cord innervating muscles, and accordingly, a long-lasting recovery by cresyl violet, were positive for ubiquitin while decreasing or losing ChAT immunoreactivity in FALS rats in motor function 6 months after grafting. A third aspect to consider is the origin of cell deterioration. In FALS (36) . Recently, it was recognized that other cell types can participate in MN death observed in transgenic romodels, gene therapy has been shown to delay MN degeneration and to lengthen animal survival when interdents modeling FALS. Nagai et al. (29) demonstrated that conditioned media of astrocytes derived from fering RNA designed to knock down hSOD1 G93A in vivo was used; the fatal outcome, however, cannot be avoided hSOD1 G93A transgenic mice caused MN death. 
